Background:
@EN Pneumococcal vaccine was licensed for general use in 1977 because of the continuing importance of Streptococcus pneumoniae as a cause of fatal infections. In general, it is believed to be highly immunogenic and relatively safe.
However, some reports suggested that immune response to pneumococcal polysaccharide vaccine might be different according to race, age and gender. In Korea, no studies regarding this hypothesis had been done, especially in healthy adult
population.
@ES Methods:
@EN We observed immunogenity and adverse effects of two 23-valent pneumococcal polysaccharide vaccines in healthy elderly subjects. 73 healthy elderly volunteers were divided into two groups and immunized with one of two different 23-valent
pneumococcal
vaccines. One group(N=37, mean age:74.4) received Pneumovax 23(MSD) and the another group (N=36, mean age:76.1) received Pneumo 23(Pasteur-Merieux Serums and Vaccine).
We took blood samples prior to and one month after vaccination. We evaluated the appearance of anticapsular IgG antibody for serotype 1,3,4,6B,8,12F,14 using enzymelinked immunosorbent assay. We also checked for adverse reactions to immunization
6,24,48, and 72 hours after vaccination.
@ES Results:
@EN Postvaccination antibody titers are significantly higher compared to that of prevaccination except serotype 3. There was no difference in the immunologic response to pneumococcal vaccination between two groups.
Approximately 41.1% of subjects developed mild side effects such as pain and swelling on the injection site, fever, myalgia, and headache; however, severe systemic side effects were not observed.
@ES Conclusion:
@EN We concluded that pneumococcal vaccines, including Pneumovax 23 and Pneumo 23 are highly immunogenic and safe. It should be used widely to reduce the occurence of serious pneumococcal diseases in high-risk population.
|